CN113166169A - Mcl-1抑制剂的新晶型，其制备方法和含有它们的药物组合物 - Google Patents

Mcl-1抑制剂的新晶型，其制备方法和含有它们的药物组合物 Download PDF

Info

Publication number
CN113166169A
CN113166169A CN201980080579.8A CN201980080579A CN113166169A CN 113166169 A CN113166169 A CN 113166169A CN 201980080579 A CN201980080579 A CN 201980080579A CN 113166169 A CN113166169 A CN 113166169A
Authority
CN
China
Prior art keywords
compound
cancer
ray powder
degrees
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980080579.8A
Other languages
English (en)
Chinese (zh)
Inventor
E·德贝茨
J·奥夫雷
M·兰什
N·勒布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Furnalis R&d Co ltd
Les Laboratoires Servier SAS
Original Assignee
Furnalis R&d Co ltd
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Furnalis R&d Co ltd, Les Laboratoires Servier SAS filed Critical Furnalis R&d Co ltd
Publication of CN113166169A publication Critical patent/CN113166169A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980080579.8A 2018-12-06 2019-12-05 Mcl-1抑制剂的新晶型，其制备方法和含有它们的药物组合物 Pending CN113166169A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306634.9 2018-12-06
EP18306634 2018-12-06
PCT/EP2019/083773 WO2020115183A1 (fr) 2018-12-06 2019-12-05 Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
CN113166169A true CN113166169A (zh) 2021-07-23

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980080579.8A Pending CN113166169A (zh) 2018-12-06 2019-12-05 Mcl-1抑制剂的新晶型，其制备方法和含有它们的药物组合物

Country Status (26)

Country Link
US (2) US12129261B2 (fr)
EP (1) EP3891156B1 (fr)
JP (1) JP7649241B2 (fr)
KR (1) KR102855345B1 (fr)
CN (1) CN113166169A (fr)
AR (1) AR117255A1 (fr)
AU (1) AU2019391329B2 (fr)
BR (1) BR112021010072A2 (fr)
CA (1) CA3121363A1 (fr)
DK (1) DK3891156T3 (fr)
EA (1) EA202191534A1 (fr)
ES (1) ES2971258T3 (fr)
FI (1) FI3891156T3 (fr)
HR (1) HRP20240211T1 (fr)
HU (1) HUE065266T2 (fr)
IL (1) IL283656B2 (fr)
LT (1) LT3891156T (fr)
MA (1) MA54379B1 (fr)
MD (1) MD3891156T2 (fr)
MX (1) MX2021006702A (fr)
PL (1) PL3891156T3 (fr)
PT (1) PT3891156T (fr)
RS (1) RS65047B1 (fr)
SI (1) SI3891156T1 (fr)
TW (1) TWI905090B (fr)
WO (1) WO2020115183A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104725397A (zh) * 2013-12-23 2015-06-24 法国施维雅药厂 噻吩并嘧啶衍生物、其制备方法以及含有它们的药用组合物
WO2016207225A1 (fr) * 2015-06-23 2016-12-29 Les Laboratoires Servier Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104725397A (zh) * 2013-12-23 2015-06-24 法国施维雅药厂 噻吩并嘧啶衍生物、其制备方法以及含有它们的药用组合物
WO2016207225A1 (fr) * 2015-06-23 2016-12-29 Les Laboratoires Servier Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA ED等: "Crystalline polymorphism of organic compounds", 《TOPICS IN CURRENT CHEMISTRY-SERIES》, vol. 198, pages 163 - 208, XP008166276, DOI: 10.1007/3-540-69178-2_5 *

Also Published As

Publication number Publication date
PT3891156T (pt) 2024-01-16
KR20210100148A (ko) 2021-08-13
ES2971258T3 (es) 2024-06-04
EP3891156A1 (fr) 2021-10-13
MX2021006702A (es) 2021-07-07
FI3891156T3 (fi) 2024-02-07
DK3891156T3 (da) 2024-02-19
SI3891156T1 (sl) 2024-03-29
US12129261B2 (en) 2024-10-29
IL283656A (en) 2021-07-29
HUE065266T2 (hu) 2024-05-28
MD3891156T2 (ro) 2024-06-30
HRP20240211T1 (hr) 2024-04-26
MA54379B1 (fr) 2023-12-29
EA202191534A1 (ru) 2021-10-27
RS65047B1 (sr) 2024-02-29
US20220017533A1 (en) 2022-01-20
MA54379A (fr) 2021-10-13
PL3891156T3 (pl) 2024-05-13
WO2020115183A1 (fr) 2020-06-11
KR102855345B1 (ko) 2025-09-03
JP7649241B2 (ja) 2025-03-19
NZ776907A (en) 2025-05-02
EP3891156B1 (fr) 2023-11-15
IL283656B1 (en) 2025-06-01
IL283656B2 (en) 2025-10-01
AU2019391329B2 (en) 2024-09-26
BR112021010072A2 (pt) 2021-08-24
JP2022511495A (ja) 2022-01-31
TW202039511A (zh) 2020-11-01
US20250011337A1 (en) 2025-01-09
AU2019391329A1 (en) 2021-07-01
TWI905090B (zh) 2025-11-21
CA3121363A1 (fr) 2020-06-11
LT3891156T (lt) 2023-12-27
AR117255A1 (es) 2021-07-21

Similar Documents

Publication Publication Date Title
EP3248983B1 (fr) Forme cristalline a de l'acide obéticholique et son procédé de préparation
US20250011337A1 (en) Crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them
EA015677B1 (ru) СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
US20240417390A1 (en) Hydrogen sulfate salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
RU2844681C2 (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
RU2847971C2 (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
HK40057196A (en) New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them
CN108473507A (zh) 噻吩并嘧啶化合物的结晶形式
EA044230B1 (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
HK40060606B (en) New crystalline forms of a thienopyrimidine as mcl-1 inhibitor
HK40060606A (en) New crystalline forms of a thienopyrimidine as mcl-1 inhibitor
CA3165764A1 (fr) Formes cristallines du voxelotor, et leurs procedes de preparation
CN114127074A (zh) 无定形乌帕拉尼单甲苯磺酸盐
EA043392B1 (ru) Новая соль ингибитора bcl-2, соответствующая кристаллическая форма, способ их получения и фармацевтические композиции, которые их содержат
JP2018535969A (ja) Ｐｄｅ１０阻害剤の固体状態形態
WO2026024591A1 (fr) Formes solides de promédicament de tryptamine
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
CN100591685C (zh) 一种医药化合物的结晶形式
HK40060608A (en) Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40057196

Country of ref document: HK